A New Approach to Neurodevelopmental Care
In India and across the world, millions of children face challenges related to neurodevelopmental disorders such as autism and ADHD. Early detection is critical—but access to timely diagnosis and structured therapy remains limited.
This is where Gabify is trying to make a meaningful difference.
The healthtech startup has raised $175,000 in a pre-seed funding round led by Inflection Point Ventures, along with additional support of ₹25 lakh under the government-backed Nidhi Seed Support Scheme.
While the funding size may appear modest, the problem Gabify is solving is massive—and deeply impactful.
Building an AI Platform for Early Screening
Founded in 2023 by Sahil Chopra, Prachi Sood, and Vasyl Leshchuk, Gabify is developing an AI-powered platform focused on early screening and therapy management.
The platform targets conditions such as:
- Autism Spectrum Disorder (ASD)
- ADHD (Attention Deficit Hyperactivity Disorder)
- Speech and communication delays
The key idea is simple but powerful:
👉 Detect early, intervene early, improve outcomes.
How the Technology Works
What sets Gabify apart is its dual AI system, which combines:
- Voice analysis
- Vision (facial and behavioural) analysis
The platform evaluates:
- Speech patterns
- Facial expressions
- Behavioural indicators
All of this is measured against clinically validated parameters, ensuring that the insights are not just technical—but medically relevant.
👨⚕️ Human-in-the-Loop Approach
Unlike many AI tools that operate fully automated, Gabify follows a human-in-the-loop model, where:
- AI performs initial screening
- Experts validate and interpret results
This ensures higher accuracy and builds trust among parents, schools, and healthcare professionals.
Early Traction and Real-World Testing
Gabify has already taken its solution beyond the lab.
The platform has been tested across:
- 35+ preschools and daycare centres
- Schools
- Hospitals
- Clinics
This early adoption indicates a strong demand for accessible and scalable neurodevelopmental care solutions.
Vision: Impacting 1 Million Children
Gabify is not just building a product—it’s building an impact-driven ecosystem.
The startup aims to reach over 1 million children by 2028, using a combination of:
- B2B partnerships (schools, hospitals)
- B2C offerings (direct to parents)
- CSR-led initiatives (social impact programs)
This hybrid approach allows the company to scale while also addressing affordability and accessibility.
How the Funding Will Be Used
The newly raised capital will support:
- Clinical validation of the platform
- Technology development and refinement
- Expansion of the team
These are critical steps for a healthtech startup, where accuracy, trust, and compliance are essential.
Recognition and Accelerator Support
Gabify has already gained recognition in the startup ecosystem.
It has been selected among the top 10 startups under DreamDeal, an initiative led by Anupam Mittal.
Additionally, the startup is part of Inflection Point Ventures’ IdeaSchool programme, which supports early-stage startups in scaling their ideas.
Why This Startup Matters
Gabify represents a growing trend where AI is being used not just for efficiency, but for social impact.
In countries like India, where:
- Specialist access is limited
- Awareness is still growing
- Early diagnosis is often delayed
Solutions like Gabify can play a transformative role.
The Road Ahead
The challenge for Gabify will be to:
- Maintain clinical accuracy at scale
- Build trust among parents and institutions
- Navigate healthcare regulations
- Expand geographically
If executed well, Gabify could become a leading platform in early childhood neurodevelopmental care.
Final Thoughts
Gabify’s $175K pre-seed round is not just another funding update—it’s a step toward solving a deeply important healthcare challenge.
By combining AI, clinical validation, and scalable distribution models, the startup is working toward a future where every child gets the support they need—at the right time.
